Literature DB >> 19504371

Hypofractionation in radiotherapy. An investigation of injured Swedish women, treated for cancer of the breast.

Sten Friberg1, Bengt-Inge Rudén.   

Abstract

BACKGROUND: The Swedish Insurance Company for Patient Injuries asked the two authors of this report to identify the Swedish women with cancer of the breast who had been injured by radiotherapy with a hypofractionated schedule. The purpose was to provide a basis on which the Company could decide if indemnification could be given.
MATERIAL AND METHODS: We define hypo-fractionation as any fraction dose exceeding 2.0 gray (Gy) per day. We set the lower limit for the "late effect" at 53.0 Gy with 2 Gy/fraction. All departments of radiotherapy in Sweden were asked to identify women who had developed brachial plexus neuropathy (BPN). Their medical records were obtained. The clinical picture of their injuries was recorded, and the absorbed dose was calculated or reconstructed. All doses, no matter in what way they were expressed, were recalculated to "late effect", presented in EQD(2 Gy) (Equalized Total Dose in 2 Gy/fraction). The latency period from therapy to onset of symptoms was also noted.
RESULTS: A variety of treatment techniques was used, fractions ranging in size from 2.5 to 6.0 Gy. Absorbed doses up to a Biologically Equivalent Dose (BED) 146 EQD(2 Gy) in late effects were recorded (6 Gy x 13). More than 95% of the injured women had a combination of stiff shoulder, paralysis, pain, oedema and atrophy of the muscles to the arm and/or hand. Latency from end of radiotherapy to onset of symptoms could be as long as 30 years. Discussion. Hypofractionated radiotherapy has injured severely numerous patients. The lesions have become a medico-legal issue in some countries. The life of many of these women has been ruined: physically, mentally, socially and economically.
CONCLUSION: Hypofractionated radiotherapy can cause injuries if the target volume is not exact, or the total dose is not adjusted to a tolerable level as compared to conventional treatments employing 2 Gy/day fractions.

Entities:  

Mesh:

Year:  2009        PMID: 19504371     DOI: 10.1080/02841860902824917

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  8 in total

1.  [Radiation Therapy to the Plexus Brachialis in Breast Cancer Patients: Analysis of Paresthesia in Relation to Dose and Volume].

Authors:  Marc D Piroth
Journal:  Strahlenther Onkol       Date:  2015-11       Impact factor: 3.621

2.  Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.

Authors:  Thomas P Boike; Yair Lotan; L Chinsoo Cho; Jeffrey Brindle; Paul DeRose; Xian-Jin Xie; Jingsheng Yan; Ryan Foster; David Pistenmaa; Alida Perkins; Susan Cooley; Robert Timmerman
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

Review 3.  Charged particle therapy--optimization, challenges and future directions.

Authors:  Jay S Loeffler; Marco Durante
Journal:  Nat Rev Clin Oncol       Date:  2013-05-21       Impact factor: 66.675

4.  DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases.

Authors:  Wilfried Budach; Christiane Matuschek; Edwin Bölke; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Marc D Piroth; Marie-Luise Sautter-Bihl; Felix Sedlmayer; Rainer Souchon; Frederik Wenz; Frederick Wenz; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2015-05-12       Impact factor: 3.621

5.  Radiotherapy for gynecologic cancer in nonagenarian patients: a framework for new paradigms.

Authors:  Benoîte Méry; Sylvie Mengue Ndong; Jean-Baptiste Guy; Avi Assouline; Alexander T Falk; Anaïs Valeille; Jane-Chloé Trone; Romain Rivoirard; Pierre Auberdiac; Alexis Vallard; Sophie Espenel; Guillaume Moriceau; Olivier Collard; Claire Bosacki; Jean-Philippe Jacquin; Guy de Laroche; Pierre Fournel; Cyrus Chargari; Nicolas Magné
Journal:  Chin J Cancer       Date:  2016-05-09

6.  Post-mastectomy and post-breast conservation surgery pain syndrome: a review of etiologies, risk prediction, and trends in management.

Authors:  Victor E Chen; Benjamin A Greenberger; Zheng Shi; Shefali Gajjar; Wenyin Shi; Waleed F Mourad; Weisi Yan
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

7.  Implementation and utilization of hypofractionation for breast cancer.

Authors:  Philip Gilbo; Louis Potters; Lucille Lee
Journal:  Adv Radiat Oncol       Date:  2018-04-09

8.  Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial.

Authors:  M S Thomsen; M Berg; S Zimmermann; C M Lutz; S Makocki; I Jensen; M H B Hjelstuen; S Pensold; M P Hasler; M-B Jensen; B V Offersen
Journal:  Clin Transl Radiat Oncol       Date:  2021-04-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.